Navigation Links
Georgia Tech develops speedy software designed to improve drug development
Date:11/17/2011

Creating new, improved pharmaceuticals is sometimes very similar to cracking the code of a combination lock. If you have the wrong numbers, the lock won't open. Even worse, you don't know if your numbers are close to the actual code or way off the mark. The only solution is to simply guess a new combination and try again.

Similarly, when a newly created drug doesn't bind well to its intended target, the drug won't work. Scientists are then forced to go back to the lab, often with very little indication about why the binding was weak. The next step is to choose a different pharmaceutical "combination" and hope for better results. Georgia Tech researchers have now generated a computer model that could help change that blind process.

Symmetry-adapted perturbation theory (SAPT) allows scientists to study interactions between molecules, such as those between a drug and its target. In the past, computer algorithms that study these noncovalent interactions have been very slow, limiting the types of molecules that can be studied using accurate quantum mechanical methods. A research team headed by Georgia Tech Professor of Chemistry David Sherrill has developed a computer program that can study larger molecules (more than 200 atoms) faster than any other program in existence.

"Our fast energy component analysis program is designed to improve our knowledge about why certain molecules are attracted to one another," explained Sherrill, who also has a joint appointment in the School of Computational Science and Engineering. "It can also show us how interactions between molecules can be tuned by chemical modifications, such as replacing a hydrogen atom with a fluorine atom. Such knowledge is key to advancing rational drug design."

The algorithms can also be used to improve the understanding of crystal structures and energetics, as well as the 3D arrangement of biological macromolecules. Sherrill's team used the software to study the interactions between DNA and proflavine; these interactions are typical of those found between DNA and several anti-cancer drugs. The findings are published this month in the Journal of Chemical Physics.

Rather than selling the software, the Georgia Tech researchers have decided to distribute their code free of charge as part of the open-source computer program PSI4, developed jointly by researchers at Georgia Tech, Virginia Tech, the University of Georgia and Oak Ridge National Laboratory. It is expected to be available in early 2012.

"By giving away our source code, we hope it will be adopted rapidly by researchers in pharmaceuticals, organic electronics and catalysis, giving them the tools they need to design better products," said Sherrill.

Sherrill's team next plans to use the software to study the noncovalent interactions involving indinavir, which is used to treat HIV patients.


'/>"/>
Contact: Jason Maderer
maderer@gatech.edu
404-385-2966
Georgia Institute of Technology
Source:Eurekalert  

Related biology news :

1. Georgia residents: Investment in global health research is vital to states economy
2. Georgia Tech team helps decode newly sequenced strawberry genome
3. Georgia State receives $6.7 million grant for research center in health disparities
4. Georgia Tech awarded a $20M Center for Chemical Innovation from NSF and NASA
5. 3 Georgian leaders sign Vienna Declaration, strengthen call for science-based drug policy
6. Georgia Powers Green Energy Program Redesigned to Include More Solar Power
7. Penn, Georgia collaboration awarded $14.6 million to expand pathogen database
8. Georgia State researcher to use $1 million grant to improve computer models for fighting wildfires
9. New center at Georgia Tech aims to improve recovery of soldiers with severe injuries
10. Georgia goes bananas
11. Georgia Stem Cell Initiative meets on MCG campus Feb. 10
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Georgia Tech develops speedy software designed to improve drug development
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, ... North America this May on the following dates: , ?    London, UK ... Chairman of the Learning and Performance Institute will be the opening keynote ...
(Date:4/25/2017)... ... ... As part of the Stago EdVantage Virtual University Virtual Event, ... order to illuminate this clinical problem for people unfamiliar with the topic. , DIC ... high degree of morbidity and mortality. DIC is a confusing disorder from both diagnostic ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/25/2017)... ... 2017 , ... Leaders of Quorum Review IRB and Kinetiq ... at this week’s Association of Clinical Research Professionals (ACRP) 2017 Meeting & Expo ... , "We are excited to present subject matter expertise on topics that impact the ...
Breaking Biology Technology: